Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
P/E ratio for Societal CDMO, Inc. (SCTL)
P/E ratio as of 2023: -2.51
According to Societal CDMO, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.51. At the end of 2022 the company had a P/E ratio of -4.34.
P/E ratio history for Societal CDMO, Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.51 |
| 2022 | -4.34 |
| 2021 | -2.85 |
| 2020 | -1.45 |
| 2019 | -10.69 |
| 2018 | -1.63 |
| 2017 | -3.09 |
| 2016 | -2.56 |
| 2015 | 22.59 |
| 2014 | -0.99 |
| 2013 | -27.15 |
| 2012 | -15.09 |
| 2011 | -8.08 |